Latest Information Update: 08 Aug 2002
At a glance
- Originator Merck & Co
- Class Anti-ischaemics; Antiplatelets; Contraceptives
- Mechanism of Action Fibrinogen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemic heart disorders; Thrombosis
Most Recent Events
- 18 Jan 1995 Phase-I clinical trials for Ischaemic heart disorders in USA (Unknown route)